Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z8IJ
|
||||
| Former ID |
DNC000971
|
||||
| Drug Name |
Muscimol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Phase 1 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C4H6N2O2
|
||||
| InChI |
InChI=1S/C4H6N2O2/c5-2-3-1-4(7)6-8-3/h1H,2,5H2,(H,6,7)
|
||||
| InChIKey |
ZJQHPWUVQPJPQT-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 94421-68-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10509, 459806, 3139249, 4361986, 6760829, 7980044, 8152653, 11111210, 11113437, 14769298, 15119776, 17390897, 24886040, 24896662, 26751672, 29223366, 47365327, 47885527, 47885528, 48110574, 49846996, 49987798, 50104370, 50190956, 53789535, 56312681, 56312683, 57322218, 85087948, 90341084, 91615052, 99233254, 99376490, 103174986, 104305902, 119525667, 124749838, 124880177, 124880178, 124880179, 125329583, 125333830, 126547189, 126600947, 126678915, 127351452, 129912243, 132506066, 134339902, 134340249
|
||||
| ChEBI ID |
ChEBI:2700
|
||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid receptor | Target Info | Agonist | [3] | |
| Glutamate receptor AMPA subtype | Target Info | Agonist | [4] | ||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4259). | ||||
| REF 2 | ClinicalTrials.gov (NCT00921128) Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease. U.S. National Institutes of Health. | ||||
| REF 3 | THIP treatment of Huntington's disease. Neurology. 1983 May;33(5):637-9. | ||||
| REF 4 | GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.